Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858883 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01858883 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 55 participants.
The verdict
NCT01858883, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- DRUG filgrastim
- DRUG itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01858883
The ClinicalTrials.gov registry entry for NCT01858883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT01858883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01858883 about?
NCT01858883 is a clinical study titled "Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors". Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
What is the current status of trial NCT01858883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2013-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01858883?
The interventions under investigation include: Gemcitabine (DRUG), nab-paclitaxel (DRUG), filgrastim (DRUG), itacitinib (DRUG).
Who is sponsoring clinical trial NCT01858883?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.